snapIoT has announced a successful integration of its mClinical platform, snapClinical, with ActiGraph’s CentrePoint System. This integration aims to give Sponsors and CROs improved power in data collection and insights for clinical trials.
ActiGraph’s medical-grade wearables and cloud-based data management platform provide a modern solution for collecting and delivering objective data points in real-time. These validated measurements provide insight into activity intensity, steps, energy expenditure, sleep time, and sleep efficiency. snapIoT’s mClinical platform delivers patient-centric mobile solutions to facilitate the collection of surveys and ePROs (electronic Patient Reported Outcomes) as well as monitor the daily operations of decentralized clinical trials. The COVID-19 crisis has made clear the need to leverage digital technologies to sustain clinical trials and protect the health of patients when normal trial operations are interrupted. The combination of digital patient monitoringalong with smart sensors provides safe methods to continue data collection via virtual outlets.
The data collected from ActiGraph’s wearables uploads to the Cloud where snapClinical can securely retrieve and store the data. With different types of measurements being collected through the sensors, snapIoT makes visualizing data simple by creating graphs that have the flexibility to overlay data points. snapClinical also allows users to easily compare these data points with other types of collected measurements, such as surveys and diaries. Sponsors and CROs can get insight into patients and ensure that they are engaged and compliant with the study protocol.
With the technology of snapIoT and ActiGraph, the integration between the two companies was accomplished in less than a week. The connectivity also makes it easy for newly validated algorithms to be implemented into the system as updates or other requirements are added. The integration provides simplistic efficiencies as the sensors are implemented directly into the snapClinical workflow engine. The power of snapIoT’s workflow engine ensures that the integration can be quickly deployed into new study protocols with minimal effort.
“We continue to drive more wearable and sensor integrations into our snapClinical platform in record timelines to fully support decentralized clinical trials. Our partnership with ActiGraph brings an industry integration to Sponsors and CROs offering a greater ability to quickly deliver a patient-centric experience,” said Isaac Eteminan, CEO of snapIoT.
“We were very impressed with snapIoT’s ability to quickly develop a platform integration to address our mutual customers’ requirements. As digital endpoints have become more prevalent, we know that providing contextual insights into patient behavior in tandem with objective sensor data is crucial in establishing the baseline for our pharma clients to make definitive regulatory claims. We’re excited about future opportunities with snapIoT, and this integration is a great start,” said Jeremy Wyatt, President & COO of ActiGraph.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.